TACE术中应用三氧化二砷CalliSpheres载药栓塞微球治疗BCLC B期原发性肝癌13例

TACE by using arsenic trioxide drug-bearing CalliSpheres beads for the treatment of BCLC stage B HCC: preliminary results in 13 patients

目的观察TACE中应用三氧化二砷(ATO)CalliSpheres Bead(CB)(CBATO)治疗BCLC B期原发性肝癌的临床疗效。方法收集2017年1月至2017年9月13例TACE术中应用CBATO治疗BCLC-B期原发性肝癌患者,对患者临床资料、影像资料、实验室检查、介入治疗的并发症和预后等情况进行总结和分析。结果 13例患者随访9～15个月,中位随访时间为11个月,生存率100%。术后1、3、6、9个月的疾病缓解率(CR+PR)分别为76.9%、76.9%、69.2%、61.5%,疾病控制率(CR+PR+SD)分别92.3%、92.3%、92.3%、84.6%。所有患者均未出现肝功能衰竭、肾功能不全、骨髓抑制、肝脓肿、胆汁漏并发感染及消化道出血等严重并发症。结论 TACE术中应用CBATO治疗原发性肝癌安全有效、近期临床疗效好。

Objective To evaluate the clinic effect of transcatheter arterial chemoembolization(TACE)by using arsenic trioxide(ATO)drug-bearing CalliSpheres beads(CB)in treating BCLC stage B hepatocellular carcinoma(HCC).Methods The clinical data of 13 patients with advanced HCC,who received TACE by using CB loaded with ATO(CBATO)during the period from January 2017 to September 2017,were retrospectively analyzed.The clinical data,imaging materials,laboratory examinations,interventional complications,prognosis,etc.,were summarized and evaluated.Results The patients were followed up for9-15 months,with a median period of 11 months.The survival rate was 100%.One,3,6 and 9 months after treatment,the disease remission(CR+PR)rates were 76.9%,76.9%,69.2%and 61.5%respectively,and the disease control rates were 92.3%,92.3%,92.3%and 84.6%respectively.In all 13 patients,no severe complications such as hepatic failure,renal insufficiency,bone marrow suppression,liver abscess,bile leakage complicated by infection and gastrointestinal bleeding occurred.Conclusion For the treatment of BCLC stage B HCC,TACE by using CBATO is safe and effective with reliable short-term effect.